TAK
NYSETakeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TAK) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 7 wire items for TAK, including 3 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published Nov 4, 2026.
TAK rankings
Financial highlights
Full financials- Revenue, FY2026
- ¥4.51T
- Revenue growth
- -1.7%
- Net income, FY2026
- -¥152.39B
- Net margin
- -3.4%
- Free cash flow, FY2026
- ¥865.43B
- Cash
- ¥595.05B
For fiscal 2026 (ended Mar 31, 2026), from SEC filings. Not investment advice.
News · 26 weeks94+75%
2026-05-102026-11-01
Mix3390d
- Insider20(61%)
- Other8(24%)
- SEC Filings4(12%)
- Earnings1(3%)
Latest news
25 items- INSIDERPresident, OBU Bitetti Teresa Marie sold $973,662 worth of American Depositary Shares (46,609 units at $20.89), decreasing direct ownership by 18% to 214,501 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- PRTakeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline MilestonesORZEYFULTM approved in the U.S., Japan and China for narcolepsy type 1 (NT1), MIMRYLOTM launched in the U.S. for erythrocytosis in polycythemia vera (PV) Zasocitinib advances to U.S. Food & Drug Administration (FDA) Priority Review and European Medicines Agency (EMA) review Late-stage pipeline continues to advance FY2026 full-year outlook upgraded to reflect foreign exchange (FX) benefit Takeda will host a Capital Markets Day on Dec. 11, 2026, in Tokyo, Japan Takeda ((4502, NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of ORZEYFUL (oveporexton) in the U.S., Japan and China, th
- PRTakeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer StudyData from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026 Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric Cancer Findings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda ((TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavat
- PRFirst and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related ComplicationMore than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16 VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda ((TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (U
- PRTakeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda ((TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for
- PRZasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily PillHead-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete skin clearance observed as early as week 8 More than 2.5 times as many patients treated with zasocitinib achieved complete skin clearance (PASI 100) at week 16 compared to deucravacitinib Additional analyses from the pivotal LATITUDE PsO 3001 and 3002 studies showed durable skin clearance and rapid and continued improvements in patient-reported itch and quality of life Takeda (NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an invest
- INSIDERChief Transformation Officer Duprey Lauren Rusckowski sold $640,279 worth of American Depositary Shares (34,535 units at $18.54), decreasing direct ownership by 15% to 191,522 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- PRU.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment ExpectationsAcceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda ((TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-g
- PRNew England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of LifeData Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies Oveporexton is the First and Only Approved Orexin Agonist Designed to Treat the Underlying Cause of NT1 and is Now Approved in the U.S., China and Japan, with Additional Regulatory Submissions Underway Takeda (NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).
- INSIDERPresident, R&D Plump Andrew Stewart sold $2,148,372 worth of American Depositary Shares (116,191 units at $18.49) as part of a pre-agreed trading plan (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- PRTakeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia VeraMIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV) MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve Fatigue Approval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda ((TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View
- PRORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda ((4502, NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor
- INSIDERPresident, R&D Plump Andrew Stewart sold $363,347 worth of American Depositary Shares (19,651 units at $18.49) as part of a pre-agreed trading plan (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Human Resources Officer Greenway Nicola Deidre Petal sold $235,118 worth of American Depositary Shares (12,980 units at $18.11), decreasing direct ownership by 24% to 40,049 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Medical Officer Farajallah Awny Samaan Botros sold $239,503 worth of American Depositary Shares (14,006 units at $17.10), decreasing direct ownership by 11% to 116,177 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, PDT BU Ibrahim Ramy Riad Ahmed sold $124,437 worth of American Depositary Shares (7,277 units at $17.10), decreasing direct ownership by 7% to 102,588 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, U.S. Business Unit Pacheco Rhonda Janice sold $289,007 worth of American Depositary Shares (16,901 units at $17.10), decreasing direct ownership by 8% to 182,507 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Transformation Officer Duprey Lauren Rusckowski sold $813,721 worth of American Depositary Shares (47,586 units at $17.10), decreasing direct ownership by 17% to 226,057 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, R&D Plump Andrew Stewart sold $2,828,220 worth of American Depositary Shares (165,393 units at $17.10), decreasing direct ownership by 18% to 766,569 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERHead, Strat. & Port. Dev Pignagnoli Agosti Marcello sold $392,565 worth of American Depositary Shares (22,957 units at $17.10), decreasing direct ownership by 11% to 176,977 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, OBU Bitetti Teresa Marie sold $855,205 worth of American Depositary Shares (50,012 units at $17.10), decreasing direct ownership by 17% to 252,010 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
TAK FAQ
11 questionsWhat does Takeda Pharmaceutical Company Limited do?
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD...What is the latest news on TAK?
In the last 30 days Quantisnow tracked 7 wire items for TAK: 3 press releases and news items, 2 SEC filings, 1 earnings update and 1 insider trade. The most recent was published on November 4, 2026.What is TAK revenue?
Takeda Pharmaceutical Company Limited (TAK) reported ¥4.51T of revenue for fiscal 2026 (ended Mar 31, 2026). That is down 1.7% from the year before.Is TAK profitable?
No. Takeda Pharmaceutical Company Limited reported a net loss of ¥152.39B for fiscal 2026 (ended Mar 31, 2026).How much cash and debt does TAK have?
Takeda Pharmaceutical Company Limited reported ¥595.05B in cash and cash equivalents and ¥4.88T of debt on its most recent balance sheet in SEC filings.Where does TAK stock trade?
Takeda Pharmaceutical Company Limited (TAK) is listed on NYSE.What sector and industry is TAK in?
Takeda Pharmaceutical Company Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Takeda Pharmaceutical Company Limited go public?
Takeda Pharmaceutical Company Limited (TAK) completed its IPO in 2018.What are analysts saying about TAK?
Across the last 6 analyst actions on Takeda Pharmaceutical Company Limited, there were 4 upgrades and 1 downgrade. The most recent action was from Bernstein: Outperform on 2026-04-08. Recent price targets range from $20.00 to $24.00.What companies are similar to TAK?
Notable peers in the same industry include ABBV (AbbVie Inc.), AZN (AstraZeneca PLC), AMGN (Amgen Inc.), BMY (Bristol-Myers Squibb Company), SNY (Sanofi). Compare TAK side-by-side with any of them on Quantisnow.How can I track TAK on Quantisnow?
Quantisnow aggregates Takeda Pharmaceutical Company Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TAK to receive live email and push alerts on every new disclosure.